Clinical trials: Graves' Ophthalmopathy
Graves' Ophthalmopathy
Thyroid-Associated Ophthalmopathy Subtypes and Orbital Antibodies
The purpose of this study is to determine whether radioactive iodine, as compared to anti-thyroid medications, is a risk factor for the development or progression of thyroid-associated ophthalmopathy in patients with…
- Trial name
- NCT00430547
- Testing
- Carbimazole, radio-active iodine (I131)
- Where
- Australia
- Volunteers
- 60 people
- Sponsor
- Barwon Health
Graves Ophthalmopathy
Sirolimus in Graves' Orbitopathy
Graves' Orbitopathy (GO) is a disabling and disfiguring condition associated with Graves' Disease, due to autoimmunity against antigens expressed by the thyroid and orbital tissues, and resulting in orbital fibroblast…
- Trial name
- RETROSIRGO (NCT05345119)
- Testing
- Sirolimus, Methylprednisolone
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- University of Pisa
Thyroid Eye Disease
The Effect of a New Antioxidant Combination (ASTED) on Moderate to Severe Thyroid Eye Disease
ASTED (Antioxidant Supplements for TED) trial is an investigator-initiated, randomized, triple masked, clinical trial of a selected combination of vitamins and minerals versus placebo in patients with moderate to severe thyroid…
- Trial name
- NCT02422368
- Testing
- Methylprednisolone + ASTED
- Where
- 2 sites in Iran
- Sponsor
- Iran University of Medical Sciences
Graves Disease, Hyperthyroidism
Impact of SSKI Pre-Treatment on Blood Loss in Thyroidectomy for Graves Disease
The purpose of this study is to determine whether a brief course of SSKI (saturated solution of potassium iodide) administered preoperatively provides any benefit in the surgical management of patients undergoing thyroidectomy as…
- Trial name
- NCT00946296
- Testing
- Potassium Iodide
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of Massachusetts, Worcester
Graves Ophthalmopathy
Genetics and Epigenetics of Graves' Orbitopathy
Graves' orbitopathy (GO) is an autoimmune disease persisting when immunosuppression is achieved. Orbital fibroblasts from GO patients display peculiar phenotypes even if not exposed to autoimmunity, possibly reflecting genetic or…
- Trial name
- GeneGO (NCT04488406)
- Testing
- No Intervention
- Where
- Italy
- Volunteers
- 12 people
- Sponsor
- University of Pisa
Thyroid Eye Disease (TED)
A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye Disease
A Multicenter, Double-blinded, Randomized, Placebo-controlled Phase 3 Study of ZL-1109 in Chinese Participants with Thyroid Eye Disease (TED)
- Trial name
- NCT07211776
- Testing
- ZL-1109 (VRDN-003)
- Where
- 26 sites in China
- Volunteers
- 108 people
- Sponsor
- Zai Lab (Shanghai) Co., Ltd.
Graves' Disease, Graves Disease
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease
The main purpose of this study is to look at how efgartigimod affects thyroid function in adults with Graves' Disease (GD). The study will also check whether efgartigimod is safe and well tolerated.
- Trial name
- VitaliThy (NCT07570316)
- Testing
- Efgartigimod PH20 SC
- Where
- 32 sites in United States, Georgia
- Volunteers
- 230 people
- Sponsor
- argenx
Thyroid Associated Ophthalmopathies, Graves´ Ophthalmopathy
Tocilizumab Treatment in Graves´ Ophthalmopathy (Graves´ Orbitopathy or Thyroid Eye Disease)
The purpose is to investigate tocilizumab administration in patients with moderately to severely or sight-threatening GO (Graves' ophthalmopathy) without response to treatment with corticoid intravenous pulses.
- Conditions
- Thyroid Associated Ophthalmopathies, Graves´ Ophthalmopathy, Thyroid Eye Disease
- Trial name
- GRC (NCT01297699)
- Testing
- Tocilizumab (RoActemra®), Sterile 0.9% Sodium Chloride
- Where
- 9 sites in Spain
- Volunteers
- 32 people
- Sponsor
- Hospital Clinico Universitario de Santiago
Graves' Disease
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
This is a study to assess the efficacy, safety, and tolerability of IMVT-1402 in adult participants with Graves' disease (GD) who are hyperthyroid despite antithyroid drug (ATD) treatment.
- Trial name
- NCT06727604
- Testing
- IMVT-1402
- Where
- 134 sites in United States, Belgium and 8 more
- Volunteers
- 240 people
- Sponsor
- Immunovant Sciences GmbH
Graves Ophthalmopathy, Graves Disease
Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy
The aim of this study is to evaluate the effects of subantimicrobial dose doxycycline (50 mg/d), administered for 12 wk, for patients with active moderate-severe Graves' Orbitopathy (GO).
- Conditions
- Graves Ophthalmopathy, Graves Disease, Eye Diseases, Thyroid Diseases
- Trial name
- NCT01727973
- Testing
- Doxycycline
- Where
- China
- Volunteers
- 14 people
- Sponsor
- Sun Yat-sen University
Graves Disease, Graves Ophthalmopathy
Impact of Intravenous Methylprednisolone Treatment on Blood Pressure
Hypertension is common side effect of Cushing Syndrome (CS): in patients with endogenous CS and those treated with glucocorticosteroids (GCs). The impact of the intravenous GCs therapy on blood pressure (BP) remains unclear.
- Conditions
- Graves Disease, Graves Ophthalmopathy, Hypertension, Blood Pressure
- Trial name
- NCT03590080
- Testing
- Methylprednisolone
- Volunteers
- 32 people
- Sponsor
- Medical University of Warsaw
Graves' Orbitopathy, Thyroid Eye Disease, TED
Early Risk Stratification of Thyroid Eye Disease in Newly Diagnosed Graves' Disease
The aim of this observational study is to investigate why some people with newly diagnosed Graves' disease (GD) develop thyroid eye disease (TED), also known as Graves' orbitopathy, while others do not.
- Conditions
- Graves' Orbitopathy, Thyroid Eye Disease, TED, Graves' Disease
- Trial name
- SOGO (NCT07812194)
- Testing
- Study-related ophthalmological assessment and biospecimen collection, Blood biomarkers and standardized blood samples including thyroid function status
- Where
- Denmark
- Volunteers
- 430 people, healthy volunteers welcome
- Sponsor
- University of Copenhagen
Thyroid Associated Ophthalmopathy
Orbital Radiotherapy in Grave's Ophthalmopathy 1 Week vs 2 Weeks (OraGO-1 Trial)
Thyroid ophthalmopathy, also known as thyroid eye disease or Graves' ophthalmopathy, is a condition characterized by inflammation and swelling of the tissues around the eyes, often accompanied by protrusion of the eyeballs.
- Trial name
- NCT06392906
- Testing
- Short course radiation therapy, Standard course radiation therapy
- Where
- Thailand
- Volunteers
- 68 people
- Sponsor
- Janjira Petsuksiri
Thyrotoxicosis, Graves Disease
Clinical Application of Pulse Rate-monitoring Activity Trackers in Thyrotoxicosis
The study is a single-center prospective cohort study of clinical application of continuously monitored data by wearable activity trackers in the patients with thyrotoxicosis.
- Conditions
- Thyrotoxicosis, Graves Disease, Thyroiditis
- Trial name
- AT-thyro (NCT03009357)
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Seoul National University Bundang Hospital
Graves Disease, Hyperthyroidism
Remission Induction and Sustenance in Graves' Disease 2
ATD therapy for Graves' disease is one of the commonly used options for therapy of the hyperthyroidism. The investigators study how to optimally keep patients in remission.
- Trial name
- NCT00796913
- Testing
- Stop medication
- Volunteers
- 139 people
- Sponsor
- Aalborg University Hospital
Hyperthyroidism, Autoimmune, Cardiovascular Abnormalities
Clinical Application of Al18F-NOTA-FAPI-04 PET/CT or PET/MRI Imaging in Malignant Tumor,Cardiovascular or Immune Disease
This prospective, single-center study investigates the biodistribution, dosimetry, safety, diagnostic performance of Al18F-NOTA-FAPI PET imaging in patients with malignant tumor,cardiovascular or immune disease.
- Conditions
- Hyperthyroidism, Autoimmune, Cardiovascular Abnormalities, Malignant Tumor
- Trial name
- NCT07400224
- Testing
- Al18F-NOTA-FAPI PET/CT(or PET/MRI)
- Where
- China
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
Graves Ophthalmopathy
Multi-center Prospective Clinical Study on Glucocorticoid Pulse Therapy for Graves' Ophthalmopathy (GO)
This study plans to include newly diagnosed, active, moderate to severe Graves' ophthalmopathy patients, divided into a high-dose group (methylprednisolone 500mg, D1-3, once every 4 weeks) and a low-dose group (methylprednisolone…
- Trial name
- GO (NCT06693856)
- Testing
- High-Dose Methylprednisolone, Low-Dose Methylprednisolone
- Where
- 3 sites in China
- Volunteers
- 120 people
- Sponsor
- Zou Junjie
Graves' Disease
A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease Ages 18 to 75 Years Old
In this study, researchers will learn more about the use of felzartamab in participants with Graves' Disease, also known as GD. GD is an autoimmune disease, which means the body's immune system attacks its own healthy cells.
- Trial name
- GRAVITATE (NCT07722546)
- Testing
- Felzartamab
- Where
- 14 sites in United States, Puerto Rico
- Volunteers
- 60 people
- Sponsor
- Biogen
Graves' Disease
Allogeneic Anti-CD19/BCMA CAR-T for Refractory Graves' Disease
Graves' disease is an autoimmune thyroid disorder in which autoantibodies against the thyroid-stimulating hormone receptor (TRAb) lead to excessive thyroid hormone production and systemic complications, as well as thyroid eye…
- Trial name
- NCT07261345
- Testing
- allogenic anti-CD19/BCMA CAR-T
- Where
- China
- Volunteers
- 4 people
- Sponsor
- Shanghai Zhongshan Hospital
Thyroid Eye Disease
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease
The purpose of this study is to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of subcutaneous (SC) satralizumab, a recombinant, humanized anti-interleukin-6 (IL-6) receptor monoclonal antibody, in…
- Trial name
- SatraGO-2 (NCT06106828)
- Testing
- Satralizumab
- Where
- 41 sites in United States, Canada and 8 more
- Volunteers
- 127 people
- Sponsor
- Hoffmann-La Roche